Taken together, we concluded that IRF4 is associated with unique molecular signatures in myeloma, leukemia, myeloma, Hodgkin’s and non-Hodgkin’s lymphomas, and that common molecular signatures associated with IRF4 in different types of non-Hodgkin’s lymphomas include BATF, LIMD1, CFLAR, PIM2, and CCND2, amongst others. Here, CCND2 is linked to plasma cell myeloma.